99 results about "Streptococcal disease" patented technology

The invention discloses a feed for improving streptococcal disease resistance of tilapia, and the feed is characterized in that: the feed is tilapia base daily ration particles containing 1% and 2% (by weight) of a compound Chinese herbal medicine water extraction solution; the compound Chinese herbal medicine water extraction solution comprises: by weight, 15% of licorice, 5% of perilla leaf, 20% of cordate houttuynia, 10% of honeysuckle flower, 15% of isatis root, 15% of hawthorn, 10% of eucommia leaf and and 10% of astragalus. Before the high temperature of the summer comes, the feed containing 2% of the compound Chinese herbal medicine water extraction solution is first fed to the tilapia for strengthening cultivation, the feed containing 1% of the compound Chinese herbal medicine water extraction solution is fed in high temperature season, the streptococcal disease infection resistant capability of the tilapia can be effectively improved, the survival rate after infection of pathogen can be increased. The Chinese herbal medicine materials in the feed are easy to obtain, are low in price, and are simple in production technology. The feed added with the compound Chinese herbal medicine has better palatability, the tilapia taking the feed may have less drug residue in the body, and the feed is in accord with requirements of green healthy aquatic products.

The invention discloses a vaccine used for preventing tilapia streptococcal disease. The vaccine is prepared by using streptococcus agalactiae and pharmaceutically acceptable excipients or carriers. The invention discloses a purpose of the vaccine in preparing medicines used for preventing tilapia streptococcal disease, and a combinatively used medicine. The invention also discloses a novel streptococcus agalactiae strain. The vaccine provided by the invention can effectively stimulate tilapia to produce immunity resisting streptococcal disease. The vaccine has a high protection rate in preventing tilapia streptococcal disease, and has high practical value and good economic benefit.

The invention relates to special compound feed for tilapia, which is prepared by the following raw materials in parts by weight: 3-8 parts of fish meal, 15-30 parts of soybean meal, 15-30 parts of rapeseed meal, 10-15 parts of cottonseed meal, 10-15 parts of DDSG (Distillers Dried Grains with Solubles), 10-20 parts of flour, 10-12 parts of corn, 4-8 parts of zeolite powder, 1-3 parts of soybean oil, 1-2 parts of fish oil, and 0.6-1.2 parts of special feed additive for the tilapia, and the sum of the parts by weight of the raw materials is 100 parts. The special compound feed for the tilapia can improve the economic benefit of tilapia culture distinctly, enhance the anti-stress capacity of the tilapia significantly, improve the immunity of the tilapia, and reduce the incidences of nutritive fatty liver diseases and streptococcicosis during the culture; a survival rate of the tilapia is increased by 16-20%; the growth of the tilapia is promoted; and the quality of fish is improved.

The invention provides a coupling substance of pneumococcoal polysaccharide carrier protein, vaccines containing the coupling substance and process for preparation, wherein the coupling substance has the structural formula of Pr-L-Ps, wherein Pr is carrier protein, Ps is pneumococcoal polysaccharide, L is covalent bond or connection group, and the mass ratio of Ps:Pr=0.5-3.5:1. The coupling substance can form protection to the homogeneous pneumococcosis protomer which produces capsular polysaccharide compositions.

The invention relates to mixed feed for improving the streptococcus resistance of tilapia, and belongs to the technical field of fish feed. The mixed feed comprises fish meal, bean pulp, double-low rape seeds, DDGS, strong flour, degossypolized cottonseed protein, wheat bran, prickly ash seeds, soybean phosphatide oil, soybean oil, methionine, levan, vitamin premix, microelement premix, vitamin C phosphate, calcium dihydrogenphosphat, mildew preventive, choline chloride and vitamin E. According to the feed, the nutrition requirement of the tilapia is taken into full consideration, the levels of protein, energy and other nutrients of the feed are scientifically adjusted, and the feed utilization rate is improved for the tilapia. The vitamin E and the levan are added to the feed and cooperate with other raw materials so that the nonspecific immunity of the tilapia can be improved, and therefore the streptococcus resistance of the tilapia is improved. The morbidity and mortality of the diseases caused by streptococcus of tilapia are reduced, and economic loss caused by the diseases caused by streptococcus of tilapia is reduced.

The invention relates to an aquaculture animal disease control technology and in particular relates to a tilapia mossambica source streptococcus agalactiae low virulent strain and application thereof. The tilapia mossambica source streptococcus agalactiae low virulent strain is YM001 and is preserved in CCTCC (China Center For Type Culture Collection) with the preservation number of CCTCCM2014045. The tilapia mossambica source streptococcus agalactiae low virulent strain is subjected to activation culture and fermentation culture, bacterial cells of a 106-109CFU/mL low virulent strain YM001 and a sterile phosphate buffered solution are mixed as a low virulent live vaccine used for preventing and controlling a tilapia mossambica streptococcus disease, the injection medication concentration for each tilapia mossambica is 105-108CFU, the oral medication concentration for each tilapia mossambica is 108-109CFU, and the soaking medication concentration is 107-108CFU/mL. The invention relates to strain identification, toxicity test, toxicity return safety and stability, immunogenicity and immune protection effect of a low virulent strain, and the tilapia mossambica streptococcus disease vaccine prepared by adopting the low virulent strain is good in immune protection effect and strong in safety and stability.

The invention discloses a compound sulphamethoxazole injection and a preparation method thereof. The injection is prepared from 5-20 % of the main drug sulphamethoxazole, 2-10 % of flunixin meglumine, 1-4 % of trimethoprim, 0.2-0.4 % of an accessory anti-oxidant, 40-70 % of an organic solvent, 0.5-2 % of an adjusting reagent and the balance being water for injection. The injection prepared by the invention can provide effective treatment for secondary infections and mixed infections of streptococcus diseases, toxoplasmosis, eperythrozoonosis, E. coli diseases, asthma and other diseases, is obvious in long-term effects, with a drug effect being enhanced by several times to dozens of times, small in application amount, few in drug using times, little in irritation and fast in performance of drug effects, saves production cost, increases added value of products, and reduces toxic and side effects due to drug mismatch during treatment.

The present invention discloses a feed for preventing and curing streptococcus iniae diseases of oreochromis mossambicus and a preparation method thereof. The feed comprises the following raw materials in parts by weight: 30-50 parts of protein powder, 3-5 parts of beet pulp, 4-6 parts of earthworm powder, 12-18 parts of sweet potatoes, 4-7 parts of cottonseed meal, 5-8 parts of rapeseed meal, 9-14 parts of flour, 1.8-3 parts of vitamins, 1-2 parts of amino acids, 1-1.8 parts of trace elements, 5-8 parts of vegetable oil, 1-2 parts of an attractant and 0.6-0.9 part of a streptococcus iniae biological preparation. The feed is prepared by the steps of sun-drying, crushing, mixing, drying, etc. The feed is reasonable in preparation and rich in nutrition, can increase the food intake amount of the oreochromis mossambicus suffering from the streptococcus iniae diseases, increases the growth speed, enhances the body immune functions, reduces the death rate of the oreochromis mossambicus suffering from the streptococcus iniae diseases and improves the cure rates.

Provided are methods for diagnosing a disease in a subject with a previous streptococcal infection by determining the presence or absence of one or more autoantibodies in a biological sample from the subject, wherein the one or more autoantibodies recognize an antigen from a protein selected from the group consisting of ELAVL2, ELAVL3, ELAVL4, Nova-1, Nova-2, Cdr1, Cdr2; and Cdr3. The presence of such autoantibodies is indicative of a positive diagnosis for a post-streptococcal disease such as PANDAS, post-GABHS glomerulonephritis, rheumatic fever, autism and Syndenham's chorea.

The invention discloses a preparation method and application of a tilapia source streptococcus agalactiae recombinant GroEL protein vaccine. The recombinant GroEL protein vaccine is prepared by tilapia source streptococcus agalactiae recombinant GroEL protein. An amino acid sequence of the tilapia source streptococcus agalactiae recombinant GroEL protein is as shown in SEQ ID NO.2. In the invention, tilapia source streptococcus agalactiae is taken as a research object, a GroEL gene is obtained from a tilapia source streptococcus agalactiae genome by cloning, the cloned GroEL gene is connected with a pET28a(+) carrier to construct an expression vector, and the vector is subjected to prokaryotic expression and purification in E.coli BL21(DE3) to obtain the recombinant GroEL protein vaccine with strong specificity and an immune protective efficacy of 68.61+/-7.39 percent, so that a foundation is laid for immune prevention and treatment of a tilapia streptococcus agalactiae disease.

The invention discloses an application of a Chinese gall extract for controlling the streptococcal disease in aquaculture animals and in particular relates to an application of a Chinese gall extract for controlling the streptococcal disease in Tilapia fish. The invention also discloses a feed with the function of controlling the streptococcal disease in Tilapia fish, which contains the Chinese gall extract. Preferably, the content of the Chinese gall extract accounts for 1% to 10% of the total weight of the feed, more preferably 1% to 5%, and most preferably 1% to 2%. When the feed containing the Chinese gall extract is used for controlling the streptococcal disease, the Chinese gall extract is directly mixed in the common commercially-available feed before feeding, so as to overcome theproblem of needing to push aquaculture animals together before applying veterinary drugs in the soaking and oral intake mode, reduce the labor intensity of aquaculture farmers, reduce the man-made interference on aquaculture farmers (particularly Tilapia fish) and avoid the stress impact on Tilapia fish. Besides, the feed containing the Chinese gall extract has the advantages of less toxicity andmore safety.

Disclosed is a vaccine for edwardsiellosis and streptococcosis in a fish. Specifically, disclosed is a vaccine for edwardsiellosis in a fish, which comprises inactivated cells of (A) an Edwardsiella tarda strain derived from the target fish, and inactivated cells of (B) an Edwardsiella tarda strain derived from a fish other than the target fish, wherein, when the strain (A) is a typical Edwardsiella tarda strain, the strain (B) is an atypical Edwardsiella tarda strain, whereas when the strain (A) is an atypical Edwardsiella tarda strain, the strain (B) is a typical Edwardsiella tarda strain. Also specifically disclosed is a vaccine for edwardsiellosis and/or streptococcosis in a fish, which comprises the components mentioned above and inactivated cells of (C) Streptococcus iniae and/or Streptococcus parauberis.

The invention discloses recombinant lactococcus lactis based on the fbsA gene of Streptococcus agalactiae. The recombinant lactococcus lactis comprises the fbsA gene of Streptococcus agalactiae or segments of the fbsA gene, the fbsA gene or the segments of the fbsA gene preferably has (or have) a sequence shown in SEQ ID No. 1, the deposit number of the recombinant lactococcus lactis is CCTCC M 2020140, and expression of recombinant FbsA protein with a theoretical molecular weight of 34.6 kDa can be induced under the culture condition that niusin exists. The invention also provides a vaccine for the Streptococcus agalactiae disease of Oreochromis sp., and the vaccine is prepared from the recombinant lactococcus lactis, and is capable of producing protective antibodies in Oreochromis sp. after Oreochromis sp. is fed with the vaccine in an immune mode of oral gavage, so that Oreochromis sp. is assisted to resist infection of Streptococcus agalactiae effectively.

The invention discloses a compound feed capable of preventing streptococcal diseases of Tilapia and a preparation method of the compound feed. The feed comprises the following components in percentage by weight: 4-8% of fish meal, 22-28% of soybean meal, 4-8% of sesame seed meal, 12-16% of corn flour, 8-10% of cotton seed cakes, 15-18% of peanut kernel meal, 13-17% of whole wheat flour, 1-2% of calcium dihydrogen phosphate, 2-4% of a premix, 1-3% of soybean oil, 0.2-0.5% of plantain herb, 0.2-0.5% of common andrographis herb and 0.2-0.5% of large bamboo leaves. The compound feed disclosed by the invention is used for breeding the Tilapia at an adult fish period, and is balanced in nutrition and reasonable in compounding ratio; Chinese herbal medicine components including the plantain herb, the common andrographis herb, the large bamboo leaves and the like are particularly added, so that the health of intestinal tracts of larval Tilapia can be effectively protected, the liver functions of the Tilapia are strengthened, the immunity of Tilapia bodies is enhanced, the capacity of the Tilapia for resisting the streptococcal diseases is improved, and the growth is promoted.

The invention relates to a novel bacillus subtilis multi-valent vector-based vaccine and application thereof. The novel bacillus subtilis multi-valent vector-based vaccine comprises a bacillus subtilis recombination strain obtained by using a genetic engineering method, wherein the bacillus subtilis recombination strain is classified and named as bacillus subtilis HT5302 and is preserved in the China Center For Type Culture Collection (CCTCC) with a preservation number of CCTCC No:M2012380. The novel bacillus subtilis multi-valent vector-based vaccine is prepared by using the bacillus subtilis recombination strain as a core. A spore with a surface having no a streptococcus agalactiae 3-glyceraldehyde-phosphate dehydrogenase (GAPDH) protein can be generated through inducing the bacillus subtilis recombination strain, and secretes a fusion protein which formed by cell-penetrating peptide and vibrio anguillarum 3-GAPDH when germinating to form a nutrient cell. The novel bacillus subtilis multi-valent vector-based vaccine has a multi-valent protection function on bacterial diseases such as streptococcicosis, vibriosis, edwardsienosis and aeromonas hydrophila.

The invention relates to a traditional Chinese medicine composition for treating streptococcicosis of tilapia mossambica. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 10-15 parts of chinese barberry roots, 8-10 parts of asarum, 3-5 parts of negundo chastetree fruits, 3-4 parts of rhizoma alismatis, 1-2 parts of groundsel, 1-2 parts of salvia miltiorrhiza, 1-2 parts of platycladi seeds, 2-3 parts of bighead atractylodes rhizome and 3-5 parts of astragalus membranaceus. A preparation method comprises the following steps of: weighing the traditional Chinese medicine raw materials in parts by weight; mixing and crushing a mixture to be about 40-60 meshes; and then packaging to obtain the product. The traditional Chinese medicine composition disclosed by the invention can effectively prevent the streptococcicosis from breaking out in a cultivation process of the tilapia mossambica; the curing rate of cultivated fish schools with the disease is up to 50-70%, so that a passive situation that the tilapia mossambica of a whole pond die once the streptococcicosis breaks out is changed and the financial loss caused by the streptococcicosis of the tilapia mossambica is reduced; and therefore, the traditional Chinese medicine composition has the very important meaning to the development of the tilapia mossambica breeding industry.

The invention provides a Tilapia mossambica cultivation method and belongs to the technical field aquaculture. The cultivation method includes: processing a cultivation pond, processing cultivation water, culturing algae and regulating water, putting Tilapia mossambica fry into the cultivation pond, feeding the Tilapia mossambica fry with preprocessed feed and the mixed powder of rhubarb, radix scutellariae and cortex phellodendri, regulating water in the early stage of cultivation, regulating water in the middle and late period of cultivation, and harvesting the Tilapia mossambica. The methodhas the advantages that the incidence rate of Tilapia mossambica streptococcicosis can be lowered effectively, the survival rate of the Tilapia mossambica can be increased, Tilapia mossambica growthcan be promoted, and Tilapia mossambica yield can be increased; the method does not antibiotics and is ecological and environmentally friendly; compared with the prior art, the method can lower the incidence rate of Tilapia mossambica streptococcicosis by more than 73.99%, increase the survival rate of the Tilapia mossambica by more than 31.22%, increase the average final weight of the Tilapia mossambica by more than 15.91% and increase the mu yield of the Tilapia mossambica by more than 52.23%.

The invention discloses an antibacterial Chinese herbal medicine compound for fishes as well as a preparation method and application of the antibacterial Chinese herbal medicine compound. The Chinese herbal medicine compound is prepared from the following crude drugs in percentage by weight: 10-20% of Chinese galls, 20-40% of immature fruits of trminalia chebula, 10-30% of pomegranate barks, 8-20% of suberect spatholobus stems and 6-20% of water banyan flowers. The crude drugs are compact in combination, the production method is simple and convenient, and the medication cost is not high. The antibacterial Chinese herbal medicine compound disclosed by the invention is capable of effectively inhibiting and killing various aquatic pathogenic bacteria, has a particularly good streptococcus-resistant effect and is an ideal safe and green oral administration product for preventing and treating bacterial diseases of fishes and particularly streptococcal diseases of tilapia mossambica; and the product is degradable and residue-free in environments and fish bodies, so that the quality safety of water environments and aquatic products can be ensured, and meanwhile, the condition that pathogenic bacteria are induced to generate drug-resistant strains is avoided.

The invention discloses streptococcus agalactiae BibA recombinant protein, as well as a coding gene, a preparation method and an application thereof. The streptococcus agalactiae BibA recombinant protein provided by the invention is a protein sequence as shown in sequence No. 2. The invention also provides the coding gene, the preparation method and application of the protein. The streptococcus agalactiae BibA recombinant protein has the beneficial effects that streptococcus agalactiae is used as a research object, streptococcus agalactiae DNA is cloned to obtain a BibA gene, the cloning and sequencing of the gene sequence are completed, the prokaryotic expression and immunizing protection of the streptococcus agalactiae are researched, a vaccine development candidate antigen with high specificity and immune protection force is obtained, and the foundation is laid for prevention of streptococcus agalactiae diseases. The streptococcus agalactiae BibA recombinant protein has the advantages that the streptococcus agalactiae BibA gene is obtained by cloning, BibA recombinant expression plasmids are constructed, the BibA recombinant protein is obtained, westernblot detection results show that the BibA recombinant protein has relatively good reactogenicity, and animal (rat) experiments prove that the recombinant protein has certain protectiveness.

The invention relates to an aquaculture animal vaccine, in particular to an attenuated live vaccine prepared from a tilapia mossambica streptococcus agalactiae natural attenuated strain TFJ0901. The streptococcus agalactiae natural attenuated strain TFJ0901 is preserved in China Center for Type Culture Collection of Wuhan University, China, and the preservation number is CCTCC NO: M 2016792. The ingredients of the attenuated live vaccine are live cells of the natural attenuated strain TFJ0901 and a phosphate buffer solution, and the cell concentration is 10<6>-10<8> CFU/ml. The vaccine has high safety and immunogenicity and can effectively prevent tilapia mossambica streptococcus agalactiae.

The invention relates to a traditional Chinese veterinary medicine compound preparation Shuanghuanglian for injection as well as a preparation technology and an application thereof. The compound preparation comprises the components in parts by weight as follows: 1300-1700 parts of honeysuckle, 1300-3700 parts of radix scutellariae and 2500-7500 parts of fructus forsythiae. Slow-release accessories comprise 150 parts of hydroxymethyl propyl cellulose and 100 parts of sodium carboxymethyl cellulose. The compound preparation contains the slow-release accessories, so that the injection time of large animals can be reduced, and the stress response of the large animals can be reduced. The traditional Chinese veterinary medicine compound preparation for injection has antiviral, antibacterial, anti-inflammatory, antipyretic, analgesic, immunity-improving effects and the like. Veterinarian clinic proves that the compound preparation can be used for treating epidemic diarrhea; transmissible gastroenteritis; necrotic enteritis; septicemia caused by various epidemic diseases; cough, dyspnea, skin cyanosis, arthrocele which are caused by chromic respiratory diseases such as streptococcosis, haemophflussuis, contagious porcine pleuropneumonia, swine plague and the like; and porcine reproductive and respiratory syndrome and cow mastitis.

The invention relates to recombinant Lactococcus lactis comprising a fusion gene of a sip gene and a pgk gene of Streptococcus agalactiae, and the fusion gene is introduced into the Lactococcus lactisby a plasmid vector. The fusion gene has a DNA sequence as shown in SEQ No. 1. The plasmid vector is a pNZ8148 vector. The lactococcus lactis is Lactococcus. lactis NZ9000. The invention further provides a tilapia mossambica streptococcus agalactiae disease vaccine. The tilapia mossambica streptococcus agalactiae disease vaccine comprises the recombinant lactococcus lactis. Wherein the recombinant lactococcus lactis is the recombinant lactococcus lactis induced by nisin. The vaccine is the vaccine administrated by oral administration and intragastric administration. The tilapia mossambica streptococcus agalactiae disease vaccine comprises the recombinant lactococcus lactis with the concentration of 2*10 <10> cfu mL <-1>, and the administration dosage is 200 [mu]L.